Skip to main content
Equibles
VCNX logo

VCNX · Vaccinex, Inc. · Metrics

Track VCNX — free

Use VCNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VCNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.06 At close · Dec 18
Rebalance outlook locked
Going-concern doubt — flagged Apr 15, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. Because management’s plans have not yet been finalized and are not within the Company’s control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”
View the 10-K filed Apr 15, 2025
Market Cap
$2.94M
Shares
2.68M

VCNX metrics

47 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.06
Market cap
$2.94M

Price action

20 metrics
Price change (1W)
-73.8%
Price change (30D)
—
Price change (3M)
-79.5%
Price change (6M)
-82.7%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
141.4%
Annualized volatility (3M)
195.3%
Beta
—
RSI (14D)
25.3
Price vs SMA 50
-67.1%
Price vs SMA 200
-79.9%
Avg volume (3M)
119,977
Relative volume
0.8
Average dollar volume
$355,435

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.9×
reciprocal yield 20.4%
P / book
—
FCF yield
-550.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-632.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-3,117.3%
Trailing 12 months
Net margin
-3,100.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$18.73M
Net income (TTM)
−$18.63M
Trailing 12 months
Diluted EPS (TTM)
$-8.88
FCF margin
-2,696.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.93

Growth

11 metrics
Revenue growth YoY
+5.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$601,000
Trailing 12 months
EPS growth YoY
-100.1%
Shares change YoY
+529.2%
Year over year · more shares
Revenue CAGR (3Y)
-12.6%
Revenue CAGR (5Y)
+2.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-717.8%
Debt / equity
—
Current ratio
0.5
EBITDA (TTM)
−$31.77M
Free cash flow (TTM)
−$16.21M
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.11M
Total assets
$2.60M
Total debt
$25,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$16.19M
Capital expenditures (TTM)
$22,000
R&D (TTM)
$12.54M
SG&A (TTM)
—
Stock compensation (TTM)
$341,000
R&D / revenue
2,087.4%
Stock compensation / revenue
56.7%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1205922 CUSIP 918640301 Visit website Investor relations